Four nurses honored for exceptional dedication to patients
Lawrence, MA /PRNewswire/ - NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced Dawn Meade as the national winner of the third annual Nurse Hero Award. Meade, a registered nurse from Illinois, received over 1,500 votes. In its third year, the campaign featured 35 nurses across the United States, nominated by patients, care partners, and colleagues and received 16,000 votes nationally. The Nurse Hero Award was designed to recognize the important role home hemodialysis (HHD) nurses play in helping patients to receive access to this life-changing dialysis therapy. NxStage will recognize Meade at a special ceremony later this month.
"I am truly amazed to be honored for doing what I wholeheartedly have a passion for doing," said Meade. "Seeing patients succeed at home and reengage in their hobbies and daily life is part of what inspires me to continue to educate patients on home hemodialysis."
In addition to Meade, NxStage also congratulated the three regional winners:
Paul Jarvis, Terrie Colvard, and Sarah Packard, representing the awards for the east, central, and west locations.
"NxStage congratulates Dawn and all of the other nominees on being recognized by their patients and peers for their commitment to providing extraordinary patient care," said NxStage President, Joe Turk. "Home hemodialysis nurses deserve this recognition and more, as they play the critical role in ensuring patients have access to life-changing HHD therapy."
For more information on NxStage and home hemodialysis with the NxStage® System One™, please visit www.NxStage.com.
The NxStage System One is a prescription device and, like all medical devices, involves some risks. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream, and blood loss due to clotting or accidental disconnection of the blood tubing set. Patients should consult with their doctor to understand the risks and responsibilities of home and/or more frequent hemodialysis using the NxStage System One. Additionally, the reported benefits of home and/or more frequent hemodialysis may not be experienced by all patients. Patients and providers are encouraged to contact their state regulators to discuss state-specific regulations that may impact dialysis in the skilled nursing facility setting.
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the FDA for home hemodialysis, home nocturnal hemodialysis and solo home hemodialysis. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners (or for patients prescribed to receive solo dialysis, alone), where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. In addition, NxStage's Nx2me Connected Health platform collects important NxStage System One and patient information for flexible viewing, monitoring and reporting that may improve patient management and patient retention, as well as simplify alternative site care. www.nxstage.com.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical technology company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. NxStage also has established a small number of dialysis clinics committed to the development of innovative care delivery models for patients with ESRD. For more information on NxStage and its products and services, please visit the Company's websites at www.nxstage.com and www.nxstagekidneycare.com.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE: NxStage Medical, Inc.Copyright 2017 PR Newswire. All Rights Reserved